Background {#Sec1}
==========

Small cell carcinoma (SCC) is one subtype of the histopathological classifications with invasive biological behavior. It was mostly found in lung cancer. Small cell carcinoma outside the lungs only accounted for 4% of all small cell carcinomas. Small cell carcinoma of the bladder (SCCB) is very rare. Since first reported in 1981, its incidence accounts for about 0.5 \~ 1% of primary bladder tumor; there has been about 1000 cases reported so far \[[@CR1]\]. The definite etiology and pathogenesis are not clear yet. Clinical treatments of SCCB have neither consistent correlation scheme nor a randomized clinical trial. Therapy modes include surgery, chemotherapy, and radiotherapy. Because of the rarity of this tumor, no prospective trials have been done to evaluate the optimal treatments \[[@CR2]\]. The aim of the present study was to describe the clinical pathological features and outcomes of the nine patients in Tongji Hospital and to review the literatures.

Methods {#Sec2}
=======

Clinicopathological features {#Sec3}
----------------------------

For this retrospective, observational study, the medical records data of the nine SCCB patients were obtained from Tongji Hospital, Huazhong University of Science and Technology from February 1980 to January 2014. The first case was diagnosed in March 1980 and the last in October 2013. Follow-up ended in January 2014. Clinical and demographic information obtained through the hospital records included clinical manifestations and follow-up. The general characteristics, clinical manifestations, the pathological and immunohistochemical characteristics, treatment options, and prognostication of the nine SCCB cases were analyzed. Statistical analysis was performed using commercially available software. Kaplan-Meier survival curves were calculated. This study was approved by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.

Literature review {#Sec4}
-----------------

In order to gain a better understanding of the clinical features of SCCB, another 119 cases reported in 56 articles (from January 1979 to March 2014) were reviewed together with the 9 cases in Tongji Hospital, Huazhong University of Science and Technology. A retrospective analysis of all the 128 SCCB cases was performed. The pathological stage, immunohistochemical markers, and survival curves of all the 128 cases were also retrospectively analyzed. Kaplan-Meier survival curves were calculated.

Results {#Sec5}
=======

Clinicopathological features {#Sec6}
----------------------------

We investigated the 9 cases including 7 males and 2 females. Their ages were between 43 and 68 years old and 56 in averages. Lesions were found in the lateral wall of bladder in 7 cases, posterior wall in 2 cases, including 1 case of multiple. The sizes of tumor ranged between 1.5 cm × 2.0 cm and 6.2 cm × 5.0 cm. Intermittent painless gross hematuria were presented in all the patients and accompanied bywaist pain in 2 cases. Five male cases had smoking history. Physical examanation found that bilateral renal percussive pain is positive in 2 cases, left renal percussive pain is positive in 1 case, and deep tenderness of bladder in 1 case. All cases were scanned by ultrasound or CT. Enlargement of lymph nodes were found in 6 cases, seminal vesicle invasion in 2 cases, and rectum or uterus invasion in 3 cases. First time pathology or biopsy found transitional cell carcinoma in 5 cases, 1 case of highly differentiated adenocarcinoma, 1 case of glandular cystitis, and 1 case of inverted papilloma (Table [1](#Tab1){ref-type="table"}).Table 1Characters of SCCB in 9 cases in Tongji HospitalCaseSexAgeSize of tumor (cm)SitesSyndromesImaging featuresPathology, stage1M666.2Left anterior wallintermittent hematuria, renal percussive painCauliflower, wide base, left hydronephrosis, retropubic unclear boundariesSmall cell cancer, T4aN2M12M683.0Posterior wallintermittent hematuria, deep tenderness of bladderCauliflower, wide base, unclear boundaries of rectumTransitional cell with small cell carcinoma T3bN0M03M436.0Left posterior wallintermittent hematuria, left waist painwide base, bilateral uronephrosis, seminal vesicle invasion, lymph node enlargementMixed carcinoma (small cell based combined with transitional cell carcinoma and adenocarcinoma) T4aN2M04M672.0Left anterior wallintermittent hematuriaPapillary, exogenous, calcificationSmall cell carcinoma T3bN0M05M642.0Left side wallHematuria, pain of bladderCauliflower, wide base, lymph node enlargementSmall cell cancer T2bN0M06F544.0Right side wallHematuria, lower limbs edemaCauliflower, lymph node enlargementSmall cell cancer with lymph node metastasis T4N1M07M673.0Posterior wallIntermittent painless hematuria,Cauliflower, wide base,Mixed carcinoma (small cell based combined with transitional cell carcinoma and adenocarcinoma) T2bN0M08M624.5Right side and top wallPainless hematuria, frequency, urgencyCauliflower, multiple, boundless, lymph node enlargementneuroendocrine small cell carcinoma with right obturator lymph node metastasis T3N1M09F702.5Right side wallHematuria, frequency, urgency, odynuriafumigating, base broad, gray whiteSmall cell carcinoma combined with some poorly differentiated transitional cell carcinoma T2N0M0

After definite diagnosis, 9 cases were treated with corresponding surgery according to different conditions and stages of tumors (Table [2](#Tab2){ref-type="table"}). Postoperative pathology showed different histopathological conclusions (Table [3](#Tab3){ref-type="table"}) (Fig. [1](#Fig1){ref-type="fig"}). When recovered from operation, 4 cases were treated with chemotherapy and only 1 case was with radiotherapy. Four cases received partial cystectomy. After at least 6-month follow-up, Kaplan-Meier survival curves for 9 cases showed survival rates (Fig. [2](#Fig2){ref-type="fig"}). According to published reports in China, we analyzed outcomes of different surgeries for the 128 SCCB patients (Fig. [3](#Fig3){ref-type="fig"}).Table 2Histopathological feature of SCCB in 9 casesNSEPCKSynCD56CgALCAEMAKi-67Li1+++++−+−2++++−−+−3++++−−−−4++−++−−+99%5+++−+−−+−6+++++−−−7++−+++−−60%8++++++−90%9+++−++−+60%*NSE* neuron specific enolase, *PCK* broad-spectrum cytokines, *Syn* synaptophysin, *CgA* addicted chromogranin A, *LCA* leukocyte common antigen, *EMA* epithelial membrane antigen, *Ki67* status labeled antigen Table 3Treatment characteristics and follow-up123456789PRB√√√√TRB√√√√LND√√√√RBI√√√√SCS√BI√√√√CT√√√√RT√TTL3 M12 M14 M\>6 M\>40 M\>18 M\>84 M36 M33 MPGSystemic metastasisMyocardial infarctionSystemic metastasisNo recurrenceSurvive without tumorSystemic metastasisSurvive without tumorAscitesCachexy*PRB* partial resection of bladder, *TRB* total resection of bladder, *LND* Lymph node dissection, *RBI* reconstruction of bladder with intestinal tract, *CS* skin colostomy surgery, *BI* bladder irrigation, *CT* chemotherapy, *RT* radiotherapy, *TTL* time to live, *PG* prognosis Fig. 1Immunohistochemical staining shows expression of different cell markers Fig. 2Kaplan-Meier survival curves for 9 cases Fig. 3Kaplan-Meier survival curves of outcomes of difference surgeries for the 128 SCCB patients. The radical cystectomy group survival rates of 1, 2, 3 years are 68.11, 46.31, 22.05%, respectively. The non-cystectomy group survival rates of 1, 2, 3 years are 49.36, 29.24, 8.03%, respectively. The mean survival time of the two groups was 23.86 and 17.77 months, respectively. There was no statistically difference between the two groups (Log-rank test, *X* ^2^ = 2.6041, *P* = 0.1066)

We also analyzed pathological types of 128 patients, in which 51/128 (39.8%) were isolated small cell carcinoma, and 72/128 (56.3%) were mixed small cell carcinoma. In all cases, tumors in 53/72 cases were combined with transitional cell carcinoma (73.6%), 8/72 with squamous cell carcinomas (11.1%), 5/72 with adenocarcinoma (6.9%), 4/72 with carcinoma in situ (5.6%), 3/72 with three kinds of cells composition (4.2%) (Fig. [4](#Fig4){ref-type="fig"}). Even in 2 cases, the tumors were composited of four kinds of cells including transitional cell carcinoma of bladder, small cell carcinoma, squamous carcinoma, and adenocarcinoma. SCCB is featured with various epithelial or nerve secretory symbols. One hundred and three out of 128 cases express one or more neuroendocrine markers such as NSE, CgA, and Syn. NSE is the most sensitive marker and its positive rate is 73.4%. EMA has the highest positive rate among epithelial symbols (62.5%) and followed by keratin (61%), CEA (50%), and Leu-M1 (43.8%) (Fig. [5](#Fig5){ref-type="fig"}). Kaplan-Meier survival curves showed the outcomes between pure small cell type and mixed cell type of SCCB are different (Fig. [6](#Fig6){ref-type="fig"}).Fig. 4Pathological stage ratio of 128 cases Fig. 5Features of immunohistochemical markers of SCCB in 128 cases Fig. 6Kaplan-Meier survival curves of outcomes among pure small cell type and mixed cell type in the 128 SCCB patients. The mixed cell type group survival rates of 1, 2, 3 years are 70.4, 50.0, 25.0%, respectively. The pure small cell type group survival rates of 1, 2, 3 years are 47.5, 24.2, 13.6%, respectively. The mean survival time of the two groups was 23.5 and 18 months, respectively. There was statistically difference between the two groups (Log-rank test, *X* ^2^ = 5.547, *P* = 0.019)

Many studies suggest that NSE, CgA, Syn, and etc. play important roles in SCCB diagnosis. Epithelial membrane antigen has no specificity, but important in differential diagnosis. For example, LCA is positive in lymphoma but not expressed in SCCB. Despite of a variety of treatments, SCCB has poor overall prognosis for fast growth, strong invasion, and early metastasis (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Kaplan-Meier survival curves of 128 SCCB after diagnosis

Discussion {#Sec7}
==========

We analyzed retrospectively nine cases with SCCB diagnosed between 1980 and 2014. Combined with published reports, we investigated clinical symptoms, histopathological characters, treatments, and prognosis to enhance the understanding of SCCB.

Incidence of bladder cancer accounted for 5% of malignant tumor, and it is the second most common urologic malignancy. Up to 95% bladder cancer are of epithelial origin, among which 90% are urothelial neoplasms and followed by squamous cell carcinoma (5--8%) and adenocarcinoma (1--2%) \[[@CR3]\]. Non-epithelial tumors are rare, such as small cell carcinoma and sarcoma. SCCB is a highly malignant tumor that occurs mainly in lung and esophagus. Extra-pulmonary small cell carcinoma accounted for 4% of all small cell carcinoma \[[@CR4]\]. The disease was firstly described in 1981 by Cramer, and its incidence accounted for 0.5--1% of primary bladder tumors. About 50% SCCB are compound bladder cancers that combined with other histological bladder tumors. Average age of incidence is about 66.9 years old and 79% patients have a history of smoking. Males have three to five times incidence higher than female. So smoking may be one of the causes of the illness. Other environmental and individual risk factors are not confirmed as the etiology, but the underlying factors include chronic cystitis, bladder stones and cystoplasty \[[@CR5]\]. Up to now, pathogenesis of SCCB is not clear. Similar to lung small cell cancer, SCCB may be associated with chromosomal aberrations, such as certain sites lacking tumor suppressor genes or chromosomes areas containing cancer-causing genes (such as c-MYC) abnormal amplification. Silence of the tumor or metastasis suppressor gene is considered to be another potential mechanism of bladder cancer \[[@CR6]\].

Histopathological forms of SCCB have no obvious difference with general bladder tumors. It belongs to a part of neuroendocrine tumor group. Characteristically, small amounts of neurosecretory granules in 150 \~ 250 nm diameter can be found under the electron microscope. About 50% SCCB contains the other kinds of cancer, such as transitional cell carcinoma, adenocarcinoma, and squamous carcinoma. It can also be associated with transitional epithelial atypical hyperplasia or carcinoma in situ. The possible reason is that SCCB is derived from the neural crest of submucosa all-around poorly differentiated stem cell population \[[@CR7]\]. SCCB diagnosis mainly depends on cystoscopic biopsy lesions and postoperative histopathological examination, such as measurements by light microscopy cell morphology, cell ultrastructure electron microscope examination, and immunohistochemical examination. Preoperative examinations also include imaging, such as CT or MRI scan, urine cytology, cystoscopy, and biopsy. Cytology of SCCB is similar with poorly differentiated squamous cell carcinoma, adenocarcinoma, and transitional cell carcinoma, so diagnostic identification relies on electron microscopy or immunohistochemistry \[[@CR8]\]. Eight cases in our report were mistaken as transitional cell carcinoma, inverted papilloma, and glandular cystitis et al. before diagnosed. Since there are clear distinctions in treatment programs between SCCB and other bladder tumors, we should raise awareness of the disease and carefully check the tissue samples in order to avoid misdiagnosis, missed diagnosis, and delay of treatment ﻿timing.

Since SCCB is clinically rare tumor, there is no standard treatment. In absence of multi-center randomized study, most treatments are multi-mode combination therapy based on single-center retrospective study, so that its variability in treatment programs is great. Most scholars believe that SCCB is a mixed cell carcinoma and advocate the preferred surgical treatment, including radical cystectomy, partial cystectomy, or transurethral resection of bladder tumors (TURBT). Parts of scholars believe that the majority of SCCB has occurred micro-metastases locally at the time of diagnosis. ﻿Therefore﻿, surgery alone is not enough and the combination of radiotherapy and chemotherapy is needed \[[@CR9]\]. In our analyzed group, 102 patients were treated with surgery in 128 cases (79.7%), in which TURBT, partial resection and radical resection account for 41/102 (40.2%), 15/102 (14.7%), and 46/102 (45.1%), respectively. We recommend surgery as the priority. Chemotherapy plays a prominent role in the management of SCCB. Bladder cancer cells are sensitive to chemotherapy, especially transitional cell cancer, but partial bladder infusion chemotherapy cannot effectively prevent cancer metastasis. Systemic chemotherapy based on platinum was previously advocated for SCCB treatment. Mackey retrospectively analyzed 106 cases of SCCB. He believed that cisplatin-based chemotherapy was an independent prognostic factor and should be used in the treatment \[[@CR10]\]. Choong thought that chemotherapy should be used on III and IV periods and not recommended for II period \[[@CR11]\]. Abbas analyzed retrospectively that the average survival time of radical cystectomy surgery combined with chemotherapy was 21 months \[[@CR12]\]. Siefker reported that neoadjuvant chemotherapy could reduce preoperative staging and was beneficial for surgical removal to prolong survival time of patients \[[@CR13]\]. Etoposide, cisplatin, and carboplatin are usually used for pure SCCB and methotrexate, vincristine, adriamycin, cyclophosphamide, etoposide, or cisplatin for SCCB combined with transitional cell carcinoma. In our study, chemotherapy (local + systemic) and radiation therapy respectively﻿﻿ account for 48.5% and 34.6% of 128 cases. Lack of unified chemotherapy treatments, chemotherapy drugs cannot be comparable. For SCCB with skull or bone metastasis, radiation therapy may be recommended. In addition, local chemotherapy via internal iliac catheter can be applied for patients with poor physical fitness or unresectable primary tumors.

Distant metastasis occurs in 78% of patients. The patients with treatments had a better median survival of 12 to 24 months compared to the patients without treatments of 4 to 5 months. Trials reported that 2-, 3-, and 5-year survival rates of SCCB were 20, 13, and 8%, respectively \[[@CR14]\]. Choong et al. studied retrospectively that 1-, 3-, and 5-year survival rates of 44 cases of SCCB were 61.4, 27.3, and 25%. In our study, the average survival time was 20.54 months; 1-, 2-, 3-, and 4-year survival rates were 57.78, 36.94, 16.61, and 2.97%, respectively.

Conclusions {#Sec8}
===========

SCCB is a malignant tumor with lower degree differentiation and a highly invasion and metastasis. It is clinically rare. Majority of patients with SCCB have hematuria symptoms. When diagnosed, it is often already advanced so that the prognosis is poor. SCCB has unique biological characteristics with positive neuroendocrine markers. The most sensitive marker is NSE that has well specification. Hence, diagnosis of SCCB depends on pathology and immunohistochemistry. Radical bladder cystectomy combined with chemotherapy or radiotherapy can improve survival time. The outcomes of different cell types of SCCB are different. Surgery is still the main treatment of SCCB, but multi-mode integrated treatment should be a better alternative. Treatment schedules of SCCB refer to the current small cell lung cancer principles. It is difficult to determine the best options through prospective studies. Early detection, diagnosis, and treatment are the key to improve or prolong the survival time of patients.
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